Helus Pharma appoints former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to the board and chair the Scientific Advisory Committee

Helus Pharma appoints Dr. Freda Lewis-Hall to its Board of Directors and names her Chair of the Scientific Advisory Committee. The company says her role will guide scientific, clinical, and regulatory governance across Helus' portfolio and advise on discovery opportunities, clinical development strategy, and regulatory pathways. The release highlights Lewis-Hall's background as a physician and biopharmaceutical executive, including more than a decade on Pfizer's Executive Leadership Team as Chief Medical Officer, plus subsequent leadership work focused on patient engagement and health equity. Helus ties the appointment to its serotonergic agonist programs for mental health, referring to its novel serotonergic agonists (NSAs) and its clinical-stage pipeline including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder.